28bio is a startup based in the United States. Brouky records 1 investor associated with the company.
28bio develops human-derived brain and peripheral nerve organoid platforms (Brain-on-a-Chip and Nerve-on-a-Chip) and delivers associated services to enable neurotoxicity, efficacy, and disease modeling for pharmaceutical research. Their CNS-3D and PNS-3D products provide functional assays for seizure liability, neuroinflammation, myelination, and Alzheimer’s disease.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.